Increased proteasome-dependent degradation of estrogen receptor-alpha by TGF-β1 in breast cancer cell lines

Journal of Cellular Biochemistry

Volumn 88, Issue 1, 2003, Pages 181-190

  Petrel, Trevor A ^a   Brueggemeier, Robert W ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Breast cancer; Cell proliferation; Estrogen receptor alpha; Proteasome; Transforming growth factor beta; Ubiquitin

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEASOME INHIBITOR; RECEPTOR PROTEIN; RNA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION;

BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; BROMODEOXYURIDINE; CELL DIVISION; CYSTEINE ENDOPEPTIDASES; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FLOW CYTOMETRY; HUMANS; LEUPEPTINS; MULTIENZYME COMPLEXES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; UBIQUITIN;

EID: 0037214267     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10353     Document Type: Review

References (47)

1. American Cancer Society. 2001. Facts and Figures.
2. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. 1988. Transforming growth factor beta: Potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res 48:3898-3904.
3. Baudino TA, Kraichely DM, Jefcoat SC, Jr., Winchester SK, Partridge NC, MacDonald PN. 1998. Isolation and characterization of a novel coactivator protein, NCoA-62, involved in vitamin D-mediated transcription. J Biol Chem 273:16434-16441.
4. Bernstein L, Henderson BE, Hanisch R, Sullivan-Halley J, Ross RK. 1994. Physical exercise and reduced risk of breast cancer in young women. J Natl Cancer Inst 86:1403-1408.
5. Bonni S, Wang HR, Causing CG, Kavsak P, Stroschein SL, Luo K, Wrana JL. 2001. TGF-beta induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. Nat Cell Biol 3:587-595.
6. Brandt R, Ebert AD. 1998. Growth inhibitors for mammary epithelial cells. Prog Mol Subcell Biol 20:197-248.
7. Calonge MJ, Massague J. 1999. Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 274:33637-33643.
8. Castoria G, Barone MV, Di Domenico M, Bilancio A, Ametrano D, Migliaccio A, Auricchio F. 1999. Nontranscriptional action of oestradiol and progestin triggers DNA synthesis. EMBO J 18:2500-2510.
9. Chen RH, Ebner R, Derynck R. 1993. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 260:1335-1338.
10. Darbre P, Yates J, Curtis S, King RJ. 1983. Effect of estradiol on human breast cancer cells in culture. Cancer Res 43:349-354.
11. Dickson RB, Lippman ME. 1995. The molecular basis of breast cancer. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA, editors. The Molecular Basis of Breast Cancer. Philadelphia: W.B. Saunders Co., p 358-387.
12. Edwards DP, Chamness GC, McGuire WL. 1979. Estrogen and progesterone receptor proteins in breast cancer. Biochim Biophys Acta 560:457-486.
13. Ferguson AT, Davidson NE. 1997. Regulation of estrogen receptor alpha function in breast cancer. Crit Rev Oncog 8:29-46.
14. Haufel T, Dormann S, Hanusch J, Schwieger A, Bauer G. 1999. Three distinct roles for TGF-beta during intercellular induction of apoptosis: A review. Anticancer Res 19:105-111.
15. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. 2000. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6:1365-1375.
16. Kelsey JL. 1979. A review of the epidemiology of human breast cancer. Epidemiol Rev 1:74-109.
17. Klinge CM. 2000. Estrogen receptor interaction with coactivators and co-repressors. Steroids 65:227-251.
18. Laborda J. 1991. 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Res 19:3998.
19. Lau KM, Mok SC, Ho SM. 1999. Expression of human estrogen receptor-alpha and -beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 96:5722-5727.
20. Lawrence DA. 1996. Transforming growth factor-beta: A general review. Eur Cytokine Netw 7:363-374.
21. Leong GM, Subramaniam N, Figueroa J, Flanagan JL, Hayman MJ, Eisman JA, Kouzmenko AP. 2001. Ski-interacting protein interacts with Smad proteins to augment transforming growth factor-beta-dependent transcription. J Biol Chem 276:18243-18248.
22. Lin X, Liang M, Feng XH. 2000. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad2 in transforming growth factor-beta signaling. J Biol Chem 275:36818-36822.
23. Liu X, Sun Y, Constantinescu SN, Karam E, Weinberg RA, Lodish HF. 1997. Transforming growth factor beta-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA 94:10669- 10674.
24. Lu SL, Kawabata M, Imamura T, Miyazono K, Yuasa Y. 1999. Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene. Biochem Biophys Res Commun 259:385-390.
25. Lykkesfeldt AE, Briand P. 1986. Indirect mechanism of oestradiol stimulation of cell proliferation of human breast cancer cell lines. Br J Cancer 53:29-35.
26. Lynch MA, Petrel TA, Song H, Knobloch TJ, Casto BC, Ramljak D, Anderson LM, DeGroff V, Stoner GD, Brueggemeier RW, Weghorst CM. 2001. Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells. Gene Expr 9:157-171.
27. Martinez LA, Chen Y, Pavone A, Fischer SM, Conti CJ. 2000. Deregulated expression of cyclin D1 overrides antimitogenic signals. Oncogene 19:315-322.
28. Moggs JG, Orphanides G. 2001. Estrogen receptors: Orchestrators of pleiotropic cellular responses. EMBO Rep 2:775-781.
29. Mustafa IA, Bland KI. 1998. Physiologic effects of steroid hormones and postmenopausal hormone replacement on the female breast and breast cancer risk. Ann Surg 228:638-651.
30. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. 1999. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 96:1858-1862.
31. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. 2001. Mechanisms of estrogen action. Physiol Rev 81:1535-1565.
32. Ravitz MJ, Wenner CE. 1997. Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. Adv Cancer Res 71:165-207.
33. Ricketts D, Turnbull L, Ryall G, Bakhshi R, Rawson NS, Gazet JC, Nolan C, Coombes RC. 1991. Estrogen and progesterone receptors in the normal female breast. Cancer Res 51:1817-1822.
34. Roberts AB. 1998. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24:111-119.
35. Ronnov-Jessen L, Petersen OW, Bissell MJ. 1996. Cellular changes involved in conversion of normal to malignant breast: Importance of the stromal reaction. Physiol Rev 76:69-125.
36. Rooke HM, Crosier KE. 2001. The smad proteins and TGFbeta signalling: Uncovering a pathway critical in cancer. Pathology 33:73-84.
37. Rosfjord EC, Dickson RB. 1999. Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia 4:229-237.
38. Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massague J. 2001. TGFbeta influences Myc, Miz-1, and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol 3:400-408.
39. Silberstein GB, Daniel CW. 1987. Reversible inhibition of mammary gland growth by transforming growth factor-beta. Science 237:291-293.
40. Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF, Brooks SC. 1990. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50:6075-6086.
41. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB. 1997. The role of transforming growth factor-beta in the regulation of estrogen receptor expression in the MCF-7 breast cancer cell line. Endocrinology 138:1498-1505.
42. Stroschein SL, Bonni S, Wrana JL, Luo K. 2001. Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN. Genes Dev 15:2822-2836.
43. Thomas HV, Key TJ, Allen DS, Moore JW, Dowsett M, Fentiman IS, Wang DY. 1997. A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. Br J Cancer 76:401-405.
44. Wojcik C, Bury M, Stoklosa T, Giermasz A, Feleszko W, Mlynarczuk I, Pleban E, Basak G, Omura S, Jakobisiak M. 2000. Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol 32:957-965.
45. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M. 1999. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18:4879-4883.
46. Yamamoto T, Saatcioglu F, Matsuda T. 2002. Cross-talk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 143:2635-2642.
47. Zentella A, Weis FM, Ralph DA, Laiho M, Massague J. 1991. Early gene responses to transforming growth factor-beta in cells lacking growth-suppressive RB function. Mol Cell Biol 11:4952-4958.